PharmaDossier
PHARMApharmadossierPharmaDossier
Pricing & Access

Biomarker documentation mismatch in oncology prior authorization

How FDA labels, NCCN pathways, and payer policies can require different biomarker proof, causing oncology prior authorization denials.

Ran Chen
Ran Chen
15 min read · Published · Source-cited

In oncology prior authorization, the most common denial reason is not clinical ineligibility. It is documentation mismatch. The patient has the right biomarker, the right tumor type, and the right line of therapy — but the proof submitted to the payer does not match the format, methodology, or specificity that the plan's PA criteria require.

A CoverMyMeds analysis of oncology prior authorization denials identified "insufficient clinical documentation" — specifically missing biomarker test results — as a leading denial reason. Example: a provider submits a PA for pembrolizumab in NSCLC but omits PD-L1 expression test results; the payer denies for insufficient documentation. The American Cancer Society Cancer Action Network (ACS CAN) and LUNGevity biomarker coverage report found that approximately half of payers examined provide coverage for TMB or MSI testing with restrictive coverage criteria, and that coverage inconsistency across payers is driven by variability in accepted testing modalities.

The problem is structural. Three independent authorities define what biomarker evidence is required for a given drug-indication pair: the FDA prescribing information (which specifies companion diagnostic requirements), the NCCN Clinical Practice Guidelines (which recommend broader biomarker testing strategies), and the payer's coverage policy (which translates both into specific PA criteria). These three sources are not always aligned, and the gaps between them are where oncology access breaks down.

This article is for oncology access coordinators, provider-office prior authorization staff, manufacturer reimbursement specialists, and payer strategy teams who need to understand where biomarker documentation mismatches occur in oncology PA, how to prevent them, and what to do when a denial arrives because the wrong proof was submitted for the right patient.

Where biomarker mismatches happen

Mismatch 1: IHC versus NGS versus PCR

The FDA label for many targeted therapies specifies a companion diagnostic — typically an FDA-approved test performed by a specific methodology. For example, a drug may require PD-L1 testing by the 22C3 pharmDx assay (IHC) for the labeled indication. But the oncologist may have ordered a comprehensive genomic profiling (CGP) panel by next-generation sequencing (NGS) that measures PD-L1 through a different methodology, or may have TMB (tumor mutational burden) data but not a formal PD-L1 TPS score.

The payer's PA criteria may accept NGS-derived PD-L1 results, or may specifically require the FDA-approved companion diagnostic. UnitedHealthcare's Medicare Advantage medical policy on molecular pathology testing, updated February 2026, specifies that biomarker testing must demonstrate clinical utility — and the payer's definition of clinical utility may or may not align with the methodology the oncologist used.

Common methodology mismatches:

Drug class FDA-required test What oncologists often order What payers may demand
HER2-targeted (breast, gastric) HER2 IHC (4B5 or 4B5 pharmDx) or ISH NGS panel with HER2 amplification IHC 3+ or ISH-positive; NGS alone may not satisfy
ALK inhibitors (NSCLC) VENTANA ALK IHC or FDA-approved FISH NGS panel with ALK rearrangement Some payers accept NGS; others require IHC/FISH
EGFR inhibitors (NSCLC) FDA-approved EGFR mutation test (PCR or NGS) NGS panel Generally accepted if NGS is validated
MSI-H/dMMR (checkpoint inhibitors) IHC for MMR proteins or PCR for MSI NGS panel with MSI score or TMB Some payers require IHC specifically; NGS MSI may be accepted
BRCA (PARP inhibitors) FDA-approved BRCA test (germline and/or somatic) NGS panel with BRCA alteration Most payers accept NGS, but may require germline confirmation
Claudin 18.2 (gastric) IHC (VENTANA CLDN18) Not yet widely ordered New biomarker; payer policies still evolving

Mismatch 2: Tissue source and specimen timing

Payer PA criteria may specify the specimen type (tissue biopsy versus liquid biopsy) and the timing (current versus archival). Common issues:

  1. Archival tissue versus fresh biopsy: The FDA label may accept testing on archival tissue, but the payer may require testing within the past 12 months, particularly if the patient has received intervening therapy that could have altered biomarker status.

  2. Liquid biopsy versus tissue biopsy: Many payers accept liquid biopsy (ctDNA) results when tissue is unavailable, but some restrict liquid biopsy to specific situations (quantity not sufficient for tissue testing, or patient unable to undergo biopsy). A patient who had a Guardant360 liquid biopsy result may face a denial if the payer's policy requires tissue-based testing as first-line methodology.

  3. Re-biopsy requirements at progression: For reauthorization after disease progression, the payer may require re-testing to confirm that the biomarker status has not changed. The oncologist may not have ordered a new biopsy, relying instead on the original biomarker result.

Mismatch 3: Compendia listing versus payer policy

The NCCN Drugs and Biologics Compendium lists uses of drugs and biologics with NCCN Category of Evidence and Consensus ratings (1, 2A, 2B, 3). Many state statutes require commercial payers to cover off-label uses that are supported by NCCN compendium listings. But the compendium listing and the payer's PA criteria may specify different evidence requirements:

  • NCCN may recommend a drug for "ESR1 mutations" without specifying the testing methodology.
  • The payer may require documentation of an ESR1 mutation by an FDA-approved test, which may not exist for that specific biomarker.
  • The FDA label may not mention ESR1 mutations at all, creating a gap between the labeled indication, the compendium listing, and the payer policy.

As of October 2025, 41 states have statutes related to coverage of oncology treatments, per Avalere Health's state statute oncology drug coverage report. These statutes vary in which compendia they reference and how they define medical appropriateness. A payer operating in multiple states may apply different PA criteria depending on the state, creating additional complexity for access teams.

Mismatch 4: Biomarker threshold definitions

Even when the biomarker is agreed upon, the threshold for positivity may differ:

  • PD-L1: The FDA label for pembrolizumab in first-line NSCLC requires TPS ≥ 50% (no EGFR/ALK alteration). Some payer policies may require TPS ≥ 1% for alternative indications. A pathology report that states "PD-L1 positive" without specifying the TPS percentage is a common documentation failure.

  • HER2: In breast cancer, HER2-positive is defined as IHC 3+ or IHC 2+ with ISH amplification. In gastric cancer, the FDA has expanded HER2-targeted therapy eligibility, but the HER2 scoring system (gestric versus breast) differs. A pathology report using breast cancer HER2 scoring for a gastric cancer patient may not satisfy the payer's criteria.

  • Microsatellite instability: MSI-H is defined differently depending on the test. PCR-based tests use a panel of markers (BAT25, BAT26, etc.) and define instability as ≥ 30% unstable loci. NGS-based tests use a computational MSI score. IHC evaluates loss of MMR protein expression (MLH1, MSH2, MSH6, PMS2). A payer that requires "dMMR by IHC" may not accept "MSI-H by NGS," even though the two are highly correlated.

How these mismatches cause denials

The denial path typically follows this sequence:

  1. Oncologist orders a broad NGS panel (e.g., FoundationOne CDx, Guardant360, Tempus xT) at diagnosis. The panel identifies the relevant biomarker alteration.

  2. PA is submitted to the payer with the NGS report as biomarker evidence.

  3. Payer's PA criteria require a specific methodology that the NGS report does not satisfy (e.g., IHC for HER2, IHC for dMMR, a specific FDA-approved companion diagnostic).

  4. PA is denied for "insufficient biomarker documentation" — not because the patient lacks the biomarker, but because the proof format is wrong.

  5. Appeal requires either re-testing with the payer's preferred methodology or a peer-to-peer review where the oncologist argues that the NGS result is sufficient. Both paths delay treatment.

The ACCC's 2025–2026 federal policy agenda identified prior authorization as its top priority, reflecting growing provider frustration with PA-related treatment delays in oncology. The CMS Interoperability and Prior Authorization Final Rule (CMS-0057-F) requires impacted payers to publicly report PA metrics by March 31, 2026, and establishes a 2027 deadline for electronic PA implementation — but neither requirement addresses biomarker documentation standards.

How to prevent biomarker documentation mismatches

Before ordering the test

  1. Check the payer's PA criteria for the specific drug. Do not assume that the FDA label or NCCN guidelines will satisfy the payer. Many payers publish their coverage policies online (Aetna Clinical Policy Bulletins, UnitedHealthcare Medical Policies, Cigna Coverage Determination Guidelines). These policies specify which test methodologies are accepted.

  2. If the payer requires a specific methodology that is not what you planned to order, either order the payer's preferred test or order both. In many cases, the cost of an additional IHC stain is far less than the cost of a PA denial and treatment delay.

  3. Document the specimen type and date. Include the biopsy date, specimen site, and whether the specimen is archival or fresh. This information should be in the pathology report but is often missing from PA submissions.

At PA submission

  1. Include the full pathology report, not just the biomarker result. The PA reviewer needs to see the methodology, the specimen, and the result in context. A summary letter that says "Patient is PD-L1 positive" without the underlying report is a common cause of documentation requests and delays.

  2. Match the biomarker description to the payer's language. If the payer's criteria say "PD-L1 TPS ≥ 50% by 22C3 pharmDx," the PA submission should use that exact language. If the result comes from a different assay, explicitly address the methodology discrepancy.

  3. Include the NCCN compendium citation if the indication is off-label. For off-label use supported by NCCN, include the specific NCCN Guidelines version, the category of recommendation, and the relevant compendium entry. Payers in states with compendia-based coverage statutes are required to consider NCCN-supported uses, but the PA submission must provide the citation.

At denial

  1. Determine whether the denial is for biomarker documentation or clinical eligibility. These are different problems with different solutions. A documentation denial can often be resolved by providing additional test results. A clinical eligibility denial requires a peer-to-peer review and may require an appeal.

  2. If the biomarker was identified by NGS and the payer requires IHC, consider whether a peer-to-peer is faster than re-testing. Many oncologists can successfully argue that NGS-identified alterations are sufficient, particularly for biomarkers where the NGS methodology is well-validated (EGFR mutations, ALK rearrangements, BRCA alterations). This is harder for PD-L1, where the scoring system is methodology-specific.

  3. For rare biomarkers where the payer's preferred methodology is not available, document why. If the patient cannot undergo re-biopsy, or if the specific IHC stain is not available at your institution, include this in the appeal. Medical necessity for using the available evidence may be accepted.

The NCCN Biomarkers Compendium as a reference tool

The NCCN Biomarkers Compendium, updated continually alongside the NCCN Clinical Practice Guidelines, provides disease-specific recommendations for biomarker testing methodology. It focuses on the biology being measured rather than specific commercial tests, which can help bridge the gap between what the oncologist ordered and what the payer requires.

However, the Biomarkers Compendium is a reference tool, not a coverage mandate. Payers are not required to follow its recommendations, and many maintain their own medical policies that may be more restrictive. Access teams should use the Biomarkers Compendium as supporting evidence in peer-to-peer reviews and appeals, not as a substitute for checking the payer's specific PA criteria.

Emerging biomarker challenges in 2026

Claudin 18.2 in gastric and gastroesophageal cancers

The 2026 NCCN Guidelines for gastric cancer now recommend comprehensive biomarker profiling including Claudin 18.2 expression, regardless of stage. Zolbetuximab-clzb, approved by the FDA in October 2024, targets Claudin 18.2–expressing tumors. But Claudin 18.2 testing methodology is still standardizing, and payer policies are inconsistent. Some payers require IHC-based Claudin 18.2 testing by the VENTANA CLDN18 assay; others may accept any validated IHC methodology. Access teams should verify the payer's specific requirements before ordering Claudin 18.2 testing.

Tumor mutational burden (TMB)

TMB is increasingly used as a biomarker for checkpoint inhibitor eligibility, though its tumor-agnostic indication remains under scrutiny. The FDA granted accelerated approval for pembrolizumab in TMB-H (TMB ≥ 10 mut/Mb) solid tumors in June 2020 and converted it to traditional approval in December 2022. Payer policies vary: some accept TMB-H as a coverage criterion, while others have restricted coverage due to ongoing debate about the appropriate TMB threshold and clinical utility across tumor types. NGS panels report TMB scores, but the threshold for "high" varies by assay. A Guardant360 TMB of 12 mut/Mb and a FoundationOne CDx TMB of 12 mut/Mb may not be equivalent due to differences in panel design and bioinformatics.

POLE/POLD1 mutations

The 2026 NCCN Guidelines now recommend that the benefit of checkpoint inhibitor–based therapy for dMMR tumors extends to patients with POLE/POLD1 mutations and hypermutated phenotypes (based on the ATOMIC trial). Payer policies have not yet caught up with this recommendation, and POLE/POLD1 testing is not yet a standard PA criterion. Access teams should expect to provide supporting literature in PA submissions that reference POLE/POLD1 status.

How access teams should build a biomarker-to-PA workflow

Step Action Purpose
1 Identify the target drug and indication Starting point for all downstream work
2 Check the FDA label for companion diagnostic requirements Regulatory baseline
3 Check the NCCN Guidelines for biomarker testing recommendations Clinical standard of care
4 Check the payer's coverage policy for specific test methodology requirements What the payer will accept
5 If gaps exist between steps 2, 3, and 4, order the payer's required test proactively Prevent documentation denial
6 Include full pathology reports with PA submission, not summaries Give the reviewer the raw data
7 Match biomarker language to the payer's PA criteria Reduce ambiguity
8 For off-label use, include NCCN compendium citation and state statute reference if applicable Legal basis for coverage
9 If denied for documentation, determine whether peer-to-peer or re-testing is faster Minimize treatment delay
10 Track denials by biomarker type and payer to identify patterns Improve future submissions

Common failure points

  1. NGS panel result submitted for an IHC-required biomarker: The most common mismatch. Solution: check the payer's PA criteria before ordering the test, and order the required methodology in addition to NGS if necessary.

  2. PD-L1 reported as "positive" without TPS percentage: Many pathology reports summarize PD-L1 as positive or negative without specifying the TPS. Payers require the specific percentage. Solution: request a revised pathology report with the TPS score.

  3. Off-label use submitted without NCCN compendium citation: The payer denies for "not medically necessary" because the use is off-label. Solution: include the specific NCCN Guidelines version, category of recommendation, and compendium entry.

  4. Archival tissue used for reauthorization after progression: The payer requires current biomarker status. Solution: document why re-biopsy is not feasible, or order a liquid biopsy as an alternative.

  5. State statute not cited in appeal: In states with compendia-based coverage statutes, the payer is legally required to consider NCCN-supported uses. Failing to cite the statute weakens the appeal. Solution: include the relevant state statute reference in all off-label PA submissions and appeals.

What to monitor next

  • CMS electronic PA implementation (2027 deadline): The CMS Interoperability and Prior Authorization Final Rule requires electronic PA for impacted payers starting in 2027. FHIR-based PA data exchange may standardize biomarker documentation fields, potentially reducing methodology mismatches — but only if payers and providers adopt consistent data standards.

  • NCCN Biomarkers Compendium payer adoption: As the Biomarkers Compendium matures, payers may increasingly reference it in coverage policies, potentially reducing the gap between NCCN recommendations and payer criteria.

  • Companion diagnostic co-development: FDA is increasingly requiring companion diagnostic co-development for targeted therapies, which may reduce methodology ambiguity. But the lag between drug approval and test availability remains a problem.

  • Liquid biopsy payer policy evolution: As liquid biopsy evidence matures, more payers are accepting ctDNA results as equivalent to tissue-based testing. Monitor plan-specific policy updates for shifts in accepted methodologies.

  • State biomarker testing legislation: Several states are considering legislation that would expand coverage for biomarker testing, potentially reducing payer discretion over which test methodologies are accepted.

This article provides general information about biomarker documentation in oncology prior authorization. It does not constitute medical advice, reimbursement guidance for any specific patient or plan, or legal guidance. Coverage policies vary by plan, state, and product. Always verify current payer criteria before submitting prior authorization requests.

Sources

Topics
OncologyPrior AuthorizationPayer PolicyCompanion DiagnosticMarket Access
Ran Chen
Contributing Editor
Ran Chen

Founder, PharmaDossier. Life-sciences operator covering market access, specialty pharma, biosimilars, and regulated healthcare growth.

Follow on LinkedIn →

Keep reading from Pricing & Access

See all →
Pricing & Access · 12 min read

Companion diagnostic denial before oncology drug prior authorization

How companion diagnostic denials block oncology drug prior authorization, and how access teams can sequence biomarker testing, appeals, and drug...

Pricing & Access · 13 min read

Electronic prior authorization readiness for specialty drugs in 2027

What manufacturers and hubs should fix before CMS electronic prior authorization rules bring FHIR, NCPDP, denial transparency, and...

Pricing & Access · 13 min read

FHIR prior authorization fields that cause specialty-drug denials

FHIR prior authorization fields that trigger specialty-drug denials, from ICD-10 specificity and labs to step history, prescriber taxonomy, and...